USA |NASDAQ |USD
|Public Float||19.36M||P/E Ratio||-|
|% Short of Float||-||Dividend (Yield)||-|
|Held by Insiders||4.71%||Ex-Dividend Date|
|Held by Institutions||81.96%||IPO Date||Feb 28, 2019|
|Dec 20||Dec 19||Dec 18|
|Sep 21||Jun 21||Mar 21|
|Jan 21, 2022||$2.25||$2.35||$2.12||$2.16||-4.00%||149.60K|
Kaleido biosciences is expected to report earnings on May 02 ,2022.
View More Details on Kaleido biosciences's 'Earnings' Section
Kaleido biosciences trades on the NASDAQ stock market in USA under the ticker symbol "KLDO". Kaleido biosciences’s stock symbol can also be displayed as "NASDAQ:KLDO".
Kaleido biosciences (NASDAQ:KLDO) is owned by 81.95% institutional shareholders and by 4.71% insiders. The rest is owned by the public.
The 3 top institutional shareholders are "Flagship Ventures Management, Inc.", "FMR Inc" and "Harbourvest Partners, LLC", representing 65.26% of Kaleido biosciences’s total shares outstanding.
Explore More Details on Kaleido biosciences's “Ownership” Section
Kaleido biosciences's key executive team includes the following managers:
Kaleido biosciences (NASDAQ:KLDO) is classified under the "Healthcare" sector and under the "Biotechnology" industry.
Currently the number of employees working for Kaleido biosciences is 82.
Kaleido biosciences (NASDAQ:KLDO) is headquartered in MA, United States.
Kaleido biosciences’s mailing address is 65 Hayden Avenue, Lexington, MA, United States, 02421.
The company’s phone number is 617 674 9000.